Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies

Provisionally accepted
  • 1Garvan Institute of Medical Research, Darlinghurst, Australia
  • 2Westmead Institute for Medical Research, Westmead, Australia

The final, formatted version of the article will be published soon.

Cold agglutinin disease is an autoimmune condition characterised by expression of self-reactive antibodies to I/i carbohydrate blood group antigens (polymers of N-acetyllactosamine or 'LacNAc' units) resulting in anaemia through the agglutination and complement-mediated destruction of red blood cells. This antibody response is dominated by antibodies of the human IGHV4-34 germline, which display a unique hydrophobic patch formed by germline-encoded tryptophan and tyrosine residues at positions 7 and 25 within framework 1 (FR1). Although the requirement for conservation of this FR1 patch for binding to the I/i carbohydrate antigen has been well established, structural insights regarding the mechanistic role of the FR1 patch have remained elusive. Intriguingly, recent papers describing IGHV4-34 antibodies bound to the glycan-adorned surface of the HIV envelope glycoprotein shed light on the utility of this FR1 surface. Rather than indirectly shaping the conformation of the conventional antigen binding site as previously proposed, the structures reveal direct interfaces between the hydrophobic FR1 patch and high mannose glycans projected by HIV. Given the stereochemical similarities between these glycans and LacNAc, these structures suggest how I/i self-antigen glycans might be similarly engaged by IGHV4-34 antibodies in a framework-centric non-CDR mode and provide a rationale for the preservation of this otherwise self-reactive antibody germline.

Keywords: Cold agglutinin autoantibodies, Cold agglutinin disease, FR1 hydrophobic patch, glycan-antibody interface, IGHV4-34 antibodies

Received: 15 Dec 2025; Accepted: 02 Feb 2026.

Copyright: © 2026 Langley, Jara, Henry, Reed, Goodnow and Christ. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: David Langley

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.